Theo MelasKyriazi - Kaleido Biosciences Independent Director

KLDO -  USA Stock  

USD 5.69  0.03  0.52%

  Director
Mr. Theo MelasKyriazi is Independent Director of the Company. Mr. MelasKyriazi joined Flagship in April 2019, and also serves as Chief Financial Officer of Levitronix Technologies, Inc., a leader in magnetically levitated pumps for microelectronics and bioprocessing applications. He spent nearly two decades at Thermo Electron Corporationrationration in a variety of roles, including six years as CFO. There, he was instrumental in raising 2 billion in equity and convertible debt and executed Initial Public Offerings for five of Thermo Fishers subsidiary companies
  Director Since 2019  MBA    
617 674 9000  http://kaleido.com
MelasKyriazi has served on the Boards of Directors of multiple private and public life science companies and is currently a Director of Evelo Biosciences, Inc. . He holds a Bachelor’s degree in economics from Harvard University and an M.B.A. from Harvard Business School.

Kaleido Biosciences Management Efficiency

Kaleido Biosciences has return on total asset (ROA) of (59.77) % which means that it has lost $59.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (161.51) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -1.23. The value of Return on Average Equity is estimated to slide to -2.37. Kaleido Biosciences Total Assets are quite stable at the moment as compared to the past year. The company's current value of Total Assets is estimated at 68.54 Million. Current Assets is expected to rise to about 58.5 M this year, although the value of Assets Non Current will most likely fall to about 10.1 M.
The company currently holds 21.19 M in liabilities with Debt to Equity (D/E) ratio of 0.3, which may suggest the company is not taking enough advantage from borrowing. Kaleido Biosciences has a current ratio of 7.23, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 9 records

DIRECTOR Since

Dennis CarsonDynavax Technologies
1997
Daniel KisnerDynavax Technologies
2010
Dan KisnerDynavax Technologies
2010
Natale RicciardiDynavax Technologies
2013
Stanley PlotkinDynavax Technologies
2005
Francis CanoDynavax Technologies
2009
Laura BregeDynavax Technologies
2015
Andrew HackDynavax Technologies
2019
Peggy PhillipsDynavax Technologies
2006
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people. Kaleido Biosciences (KLDO) is traded on NASDAQ Exchange in USA. It is located in 65 Hayden Avenue and employs 82 people. Kaleido Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Kaleido Biosciences Leadership Team

Elected by the shareholders, the Kaleido Biosciences' board of directors comprises two types of representatives: Kaleido Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kaleido. The board's role is to monitor Kaleido Biosciences' management team and ensure that shareholders' interests are well served. Kaleido Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kaleido Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geoffrey Maltzahn, President Co-Founder
Jeremy Buzzard, Senior Vice President - Corporate Development
Johannes Vlieg, Chief Scientific Officer
Jerald Korn, General Counsel, Corporate Secretary
Grady Burnett, Director
Mike Bonney, Chairman of the Board, CEO
Bonnie Bassler, Director
John Sculley, Director
Ruth ThieroffEkerdt, Chief Medical Officer
Jeffery Moore, Senior Vice President - Finance & Administration
Theo MelasKyriazi, Independent Director
Clare Fisher, Chief Business Officer

Kaleido Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kaleido Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kaleido Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamental Analysis Now

   

Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.